Intelligence · Clinical Pipeline
Iovance Biotherapeutics Pipeline
All ClinicalTrials.gov programs at Iovance Biotherapeutics — phase, modality, and trial IDs.
- Programs
- 21
Quick answer
Iovance Biotherapeutics has 21 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.
-
Aldesleukin
Iovance Biotherapeutics B.V.
Bone Sarcoma
1 trial -
Autologous Tumor Infiltrating Lymphocytes MDA-TIL
Iovance Biotherapeutics B.V.
Malignant Solid Neoplasm
1 trial -
Cyclophosphamide
Iovance Biotherapeutics B.V.
Metastatic Bladder Urothelial Carcinoma
1 trial -
Cyclophosphamide
Iovance Biotherapeutics B.V.
Clinical Stage IV Cutaneous Melanoma AJCC v8
1 trial -
E7 TCR-T cells
Iovance Biotherapeutics B.V.
Cervical Cancer
1 trial -
E7 TCR-T cells
Iovance Biotherapeutics B.V.
HPV-Associated Cervical Carcinoma
1 trial -
FLUDARABINE PHOSPHATE, ALDESLEUKIN, LN-145, FLUDARABINE PHOSPHATE, CYCLOPHOSPHAMIDE
Iovance Biotherapeutics B.V.
Recurrent, metastatic, or persistent Cervical Carcinoma
1 trial -
Fludarabine Teva 25 mg/ml solution à diluer pour injection ou perfusion, Fludarabine phosphate 25 mg/ml Concentrate for Solution for Injection or Infusion, LN-145, Proleukin 18 x 106 IE Poeder voor oplossing voor injectie of infusie, Cyclophosphamide Injection 1 g., Fludarabine 50mg Powder For Solution For Injection Or Infusion, Endoxan, Флударабин Актавис 25 mg/ml концентрат за инжекционен или инфузионен разтвор, Fludarabinefosfaat – PCH 25 mg/ml, concentraat voor oplossing voor injectie/infusie, FLUDARAB
Iovance Biotherapeutics B.V.
Metastatic Non-Small-Cell Lung Cancer
1 trial -
IOV-3001
Iovance Biotherapeutics B.V.
Unresectable Melanoma
1 trial -
IOV-4001
Iovance Biotherapeutics B.V.
Unresectable Melanoma
1 trial -
LN-145
Iovance Biotherapeutics B.V.
Squamous Cell Carcinoma of the Head and Neck
1 trial -
LN-145
Iovance Biotherapeutics B.V.
Cervical Carcinoma
1 trial -
LN-145
Iovance Biotherapeutics B.V.
Cutaneous Squamous Cell Carcinoma
1 trial -
LN-145
Iovance Biotherapeutics B.V.
Metastatic Non Small Cell Lung Cancer
1 trial -
LN-145
Iovance Biotherapeutics B.V.
Non Small Cell Lung Cancer
1 trial -
LN-145, ALDESLEUKIN, Lifileucel, Fludarabine 50mg Powder For Solution For Injection Or Infusion, Fludarabine phosphate 25 mg/ml Concentrate for Solution for Injection or Infusion, NIVOLUMAB, Флударабин Актавис 25 mg/ml концентрат за инжекционен или инфузионен разтвор, KEYTRUDA 25 mg/mL concentrate for solution for infusion, Fludarabine Accord 25 mg/ml koncentratas injekciniam ar infuziniam tirpalui, IPILIMUMAB, Cyclophosphamide Injection 1 g.
Iovance Biotherapeutics B.V.
Neoplasm
1 trial -
Lifileucel
Iovance Biotherapeutics B.V.
Endometrial Cancer
1 trial -
Lifileucel
Iovance Biotherapeutics B.V.
Melanoma (Skin Cancer)
1 trial -
Lifileucel
Iovance Biotherapeutics B.V.
Metastatic Melanoma
2 trials -
PROLEUKIN® 18 x 106 IU Powder for solution for injection or infusion, Lifileucel, Cyclophosphamide Injection 1 g, FLUDARABINE
Iovance Biotherapeutics B.V.
Previously treated advanced melanoma
1 trial -
Tumor infiltrating lymphocytes (TIL) LN-145
Iovance Biotherapeutics B.V.
Metastatic Triple Negative Breast Cancer
1 trial
Frequently asked questions
How many pipeline programs does Iovance Biotherapeutics have?
21 published programs are linked to this sponsor in our ClinicalTrials.gov index.
Is this the complete company pipeline?
This hub lists all published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.
Data attribution: Data sources · All pipeline programs